On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
-
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
-
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
-
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
-
REGULATORY Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
-
REGULATORY Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up
January 28, 2026
-
REGULATORY Former LDP Lawmakers Outline Drug Policy Priorities in Comeback Bids
January 28, 2026
-
BUSINESS Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology
January 27, 2026
-
REGULATORY Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval
January 26, 2026
-
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
-
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
-
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026
-
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
-
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
-
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
-
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
-
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
-
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
REGULATORY Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
-
REGULATORY Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…